Clinical Trials
15 trialsNCT03025256 2026-05-05
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05341349 2026-04-23
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Terminated
NCT07501117 2026-03-30
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Herlev Hospital
Phase 1 Not yet recruiting
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT04283890 2025-09-09
CHOPIN
Leiden University Medical Center
Phase 1/2 Active not recruiting
NCT05004025 2025-08-15
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
HonorHealth Research Institute
Phase 1 Completed
NCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03472586 2025-04-24
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Thomas Jefferson University
Phase 2 Completed
NCT05169957 2024-11-05
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01585194 2024-07-09
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02519322 2024-04-05
Neoadjuvant and Adjuvant Checkpoint Blockade
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02831933 2023-09-21
ENSIGN
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT03528408 2023-04-11
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Phase 2 Unknown
NCT02626962 2022-03-22
GEM1402
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT02913417 2021-04-19
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
California Pacific Medical Center Research Institute
Phase 1/2 Unknown